The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control

Expert Opinion on Investigational Drugs

Volumn 10, Issue 10, 2001, Pages 1819-1830

  Decker, M W ^a   Meyer, M D ^a   Sullivan, J P ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Analgesia; Antinociception; Nicotinic acetylcholine receptors; Pain

Indexed keywords

2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; 3 (2 AZETIDINYLMETHOXY)PYRIDINE; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 3 (6 CHLORO 3 PYRIDAZINYL) 3,8 DIAZABICYCLO[3.2.1]OCTANE; 5 (2 AZETIDINYLMETHOXY) 2 CHLOROPYRIDINE; ANALGESIC AGENT; DIHYDRO BETA ERYTHROIDINE; EPIBATIDINE; HEXAMETHONIUM; MECAMYLAMINE; METHYLLYCACONITINE; MORPHINE; N METHYL 4 (3 PYRIDINYL) 3 BUTENAMINE; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; RECEPTOR SUBTYPE; SIB 1663; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; BINDING AFFINITY; BINDING SITE; BRAIN STEM; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOXICITY; MOUSE; NONHUMAN; PAIN; PHASE 2 CLINICAL TRIAL; RAT; REVIEW; RODENT;

ANIMALS; HUMANS; NICOTINIC AGONISTS; PAIN; PAIN MEASUREMENT; RECEPTORS, NICOTINIC;

EID: 0034774023     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.10.1819     Document Type: Review

References (96)

1. Opioid analgesics and antagonists
2. Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout
3. Pharmacology of neuropathic pain
4. Cyclooxygenase 2 inhibitors: Discovery, selectivity and the future
5. Emerging molecular approaches to pain therapy
6. Therapeutic potential of neuronal nicotinic acetylcholine receptor agonists as novel analgesics
7. The promise and pitfalls of a nicotinic cholinergic approach to pain management
8. Human neuronal nicotinic receptors
9. The nicotinic acetylcholine receptor: An allosteric protein prototype of ligand-gated ion channels
10. The molecular biology of neuronal nicotinic acetylcholine receptors
11. The alpha-bungarotoxin-binding nicotinic acetylcholine-receptor from rat-brain contains only the alpha-7 subunit
12. Neuronal alpha-bungarotoxin receptors are alpha 7 subunit homomers
13. A subtype of nicotinic cholinergic receptor in rat brain is composed of α4 and β2 subunits and is upregulated by chronic nicotine treatment
14. Neuronal nicotinic receptor expression in sensory neurons of the rat trigeminal ganglion: Demonstration of α3β4, a novel subtype in the mammalian nervous system
15. Neuronal nicotinic acetylcholine receptors in rat trigeminal Ganglia
16. Neuronal nicotinic receptors: New targets in the treatment of pain
17. Nicotinic acetylcholine receptor-targeted compounds: A summary of the development pipeline and therapeutic potential
18. Visceral pain
19. Alkaloids from frog skin: The discovery of epibatidine and the potential for developing novel non-opioid analgesics
20. (±)-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors
21. (±)-Epibatidine can differentially evoke responses mediated by putative subtypes of nicotinic acetylcholine receptors (nAChRs)
22. Epibatidine, a potent analgetic and nicotinic agonist
23. Epibatidine: High potency and broad spectrum activity on neuronal and neruomuscular nicotinic acetylcholine receptors
24. Epibatidine and pain
25. Differences between the antinociceptive effects of the cholinergic channel activators A-85380 and (+/-)-epibatidine in rats
26. Analgesic profile of the nicotinic acetylcholine receptor agonists, (+)-epibatidine and ABT-594 in models of persistent inflammatory and neuropathic pain
27. Nicotinic cholinergic receptors: Potential targets for inflammatory pain relief
28. Antihyperalgesic activity of epibatidine in the formalin model of facial pain
29. A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: In vitro pharmacological properties of a novel, high affinity alpha 4 beta 2 nicotinic acetylcholine receptor ligand
30. Broad spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors
31. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine] - A novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors - I - In vitro characterization
32. Structure-activity studies related to ABT-594, a potent nonopioid analgesic agent - Effect of pyridine and azetidine ring substitutions on nicotinic acetylcholine receptor binding affinity and analgesic activity in mice
33. Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via reuronal ricotinic acetylcholine receptors
34. Discovery of ABT-594 and related neuronal nicotinic acetylcholine receptor modulators as analgesic agents: Medicinal chemistry and biology
35. The identification of novel structural compound classes exhibiting high affinity for neuronal nicotinic acetylcholine receptors and analgesic efficacy in preclinical models of pain
36. ABT-594, a novel cholinergic channel modulator, is efficacious in nerve ligation and diabetic neuropathy models of neuropathic pain
37. Antinociceptive effects of the novel neuronal nicotinic acetylcholine receptor agonist, ABT-594, in mice
38. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine] - A novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors. II. in vivo characterization
39. Analgesic and toxic effects of ABT-594 resemble epibatidine and nicotine in rats
40. Mono- and disubstituted-3,8-diazabicyclo[3.2.1]octane derivatives as analgesics structurally related to epibatidine - Synthesis, activity, and modeling
41. Antinociceptive profile of the new nicotinic agonist DBO-83
42. Conformationally restricted analogs of nicotine and anabasine
43. Synthesis, optical resolution, absolute configuration and preliminary pharmacology of (+) and (-)-cis-2,3,3a,4,5,9b-hexahydro-1-methyl-1H-pyrrolo [3,2-h]isoquinoline, a structural analog of nicotine
44. RJR-2403: A nicotinic agonist with CNS selectivity I. In vitro characterization
45. Antinociceptive and pharmacological effects of metanicotine, a selective nicotinic agonist
46. Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo
47. 3-[2,4-dimethoxybenzylidene] anabaseine (DMXB) selectively activates rat α7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner
48. Diversity of neuronal nicotinic acetylcholine receptors: Lessons from behavior and implications for CNS therapeutics
49. ABT-089 [2-methyl- 3(2-(S)-pyrrolidinylmethoxy)pyridine] .1. a potent and selective cholinergic channel modulator with neuroprotective properties
50. ABT-089 [2-methyl-3(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: Discriminative stimulus properties and electrophysiological actions
51. Protective effect of GTS-21, a novel nicotinic receptor agonist, on delayed neuronal death induced by ischemia in gerbils
52. Is epibatidine really analgesic? Dissociation of the activity, temperature, and analgesic effects of (±)-epibatidine
53. Antinociceptive responses to nicotinic acetylcholine receptor ligands after systemic and intrathecal administration in mice
54. Evaluation of anti-nociceptive effects of neuronal nicotinic acetylcholine receptor (nAChR) ligands in the rat tail-flick assay
55. The antinociceptive effects of alpha 7 nicotinic agonists in an acute pain model
56. Reduced antinociception in mice lacking neuronal nicotinic receptor subunits
57. Reduced nicotinic receptor-mediated antinociception following in vivo antisense knock-down in rat
58. Different methods of assessing nicotine-induced antinociception may engage different neural mechanisms
59. Characterization of the antinociception induced by nicotine in the pedunculopontine tegmental nucleus and the nucleus raphe magnus
60. Role of the nucleus raphe magnus in antinociception produced by ABT-594 - Immediate early gene responses possibly linked to neuronal nicotinic acetylcholine receptors on serotonergic neurons
61. The antinociception produced by microinjection of a cholinergic agonist in the ventromedial medulla is mediated by noradrenergic neurons in the A7 catecholamine cell group
62. Intrathecal clonidine alleviates allodynia in neuropathic rats - Interaction with spinal muscarinic and nicotinic receptors
63. The role of neuronal nicotinic acetylcholine receptors in antinociception: Effects of ABT-594
64. Multiple spinal mediators in parenteral nicotine-induced antinociception
65. Spinal mechanisms underlying A-85380-induced effects on acute thermal pain
66. Effects of microdialyzed oxotremorine, carbachol, epibatidine, and scopolamine on intraspinal release of acetylcholine in the rat
67. Epibatidine binding sites and activity in the spinal cord
68. Nociceptive and antinociceptive responses to intrathecally administered nicotinic agonists
69. A-85380 and epibatidine each interact with disparate spinal nicotinic receptor subtypes to achieve analgesia and nociception
70. Sex differences in cholinergic analgesia in normal rats
71. Sex differences in cholinergic analgesia II: Differing mechanisms in two models of allodynia
72. Sex differences in cholinergic analgesia I: A supplemental nicotinic mechanism in normal females
73. Presynaptic nicotinic ACh receptors
74. The effect of chronic administration of nicotine on antinociception, opioid receptor binding and met-enkelphalin levels in rats
75. Nicotine modulates evoked GABAergic transmission in the brain
76. Altered neuroadaptation in opiate dependence and neurogenic inflammatory nociception in alpha CGRP-deficient mice
77. 2+/calmodulin-protein kinase II in nicotine-induced antinociception in mice
78. Naloxone precipitates nicotine abstinence syndrome in the rat
79. Nicotine potentiates morphine antinociception: A possible cholinergic mechanism
80. The development of cross-tolerance between morphine and nicotine in mice
81. Pharmacological effects of epibatidine optical enantiomers
82. Pain inhibition, nicotine, and gender
83. Tobacco product regulation: Context and issues
84. Transdermal nicotine: Reduction of smoking with minimal abuse liability
85. A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler
86. Acetylcholine-receptors containing the β2 subunit are involved in the reinforcing properties of nicotine
87. Nicotine-induced place preferences following prior nicotine exposure in rats
88. 3H]epibatidine binding in response to repeated nicotine administration in rats
89. Mecamylamine blocks the development of tolerance to nicotine in rats: Implications for the mechanisms of tolerance
90. Associative tolerance to nicotine analgesia in the rat: Tail-flick and hot-plate tests
91. Tolerance to the antinociceptive effect of epibatidine after acute and chronic administration in mice
92. Sex differences in supraspinal morphine analgesia are dependent on genotype
93. Pharmacogenetic variability in neuronal nicotinic receptor-mediated antinociception
94. Sex differences in cocaine- and nicotine-induced antinociception in the rat
95. Influence of gender and sex hormones on nicotine acute pharmacological effects in mice
96. 1 (substance P) receptor antagonists - Why are they not analgesic in humans?